A new experimental treatment could fundamentally change how doctors battle one of the world's fastest-growing liver diseases, one that often progresses silently for years before turning deadly.
Researchers at UC San Diego reported that ION224, a drug designed to shut down fat production inside the liver, produced significant improvements in patients with metabolic dysfunction-associated steatohepatitis (MASH), an aggressive form of fatty liver disease linked to obesity and type 2 diabetes. The findings, published in The Lancet, caught attention because the drug targets the disease mechanism itself rather than simply encouraging weight loss or managing symptoms.
MASH can quietly destroy liver tissue for years, eventually triggering cirrhosis, liver failure, or cancer. As many as one in four adults globally may carry some form of fatty liver disease, with more than 100 million Americans affected. Many never know they have it because symptoms typically emerge only after serious damage has already occurred.
How It Works
ION224 blocks DGAT2, an enzyme that helps the liver produce and store fat. Scientists believe excess fat inside liver cells triggers inflammation, tissue scarring, and progressive damage over time. By interrupting this mechanism at its root, the drug stops fat accumulation and inflammation directly in the organ.
"This is the first drug of its kind to show real biological impact in MASH," said Rohit Loomba, principal investigator and chief of the Division of Gastroenterology and Hepatology at UC San Diego School of Medicine. "If these findings are confirmed in Phase III trials, we may finally be able to offer patients a targeted therapy that halts and potentially reverses liver damage before it progresses to life-threatening stages."
The approach matters because many current treatments focus primarily on weight loss. ION224 appeared to improve liver health even when patients did not lose significant weight, suggesting it could eventually complement popular GLP-1 weight loss medications and other therapies.
A Phase IIb trial enrolled 160 U.S. adults with MASH and mild to moderate liver fibrosis. Participants received monthly injections of ION224 at varying doses or placebo over 51 weeks. Those receiving the highest dose showed the strongest results, with about 60% experiencing meaningful improvements in liver health compared to placebo. The medication was generally well tolerated, with no serious side effects linked to the drug.
The study is considered notable because it is the first to demonstrate that blocking DGAT2 with antisense therapy can improve liver inflammation and fibrosis in MASH patients. Researchers also noted the treatment avoided some dangerous side effects seen with other drugs targeting liver fat production, including harmful increases in triglycerides.
Scientists increasingly view DGAT2 as a key driver of inflammation and fibrosis in MASH because the enzyme plays a major role in de novo lipogenesis, the body's process for creating fat in the liver. Future treatment strategies may involve pairing liver-targeted drugs like ION224 with medications that improve weight loss, insulin resistance, or overall metabolic health.
Larger Phase III clinical trials will next test the drug's safety and effectiveness in a broader patient population before regulators consider approval.
Author Jessica Williams: "This could finally give doctors a weapon that actually stops the disease instead of just managing the symptoms, but the real test comes when they scale up to Phase III."
Comments